The stock price of Qiagen NV (NYSE: QGEN) has plunged by -1.25 when compared to previous closing price of 44.91, but the company has seen a 0.54% gain in its stock price over the last five trading sessions. zacks.com reported 2024-10-01 that QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
Is It Worth Investing in Qiagen NV (NYSE: QGEN) Right Now?
Qiagen NV (NYSE: QGEN) has a price-to-earnings ratio that is above its average at 141.33x. The stock has a 36-month beta value of 0.40. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 0 as “overweight,” 7 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for QGEN is 221.24M, and at present, short sellers hold a 1.58% of that float. On October 03, 2024, the average trading volume of QGEN was 1.25M shares.
QGEN’s Market Performance
QGEN’s stock has seen a 0.54% increase for the week, with a 0.16% rise in the past month and a 9.29% gain in the past quarter. The volatility ratio for the week is 1.43%, and the volatility levels for the past 30 days are at 1.50% for Qiagen NV The simple moving average for the past 20 days is -2.02% for QGEN’s stock, with a 1.74% simple moving average for the past 200 days.
Analysts’ Opinion of QGEN
Many brokerage firms have already submitted their reports for QGEN stocks, with Wolfe Research repeating the rating for QGEN by listing it as a “Outperform.” The predicted price for QGEN in the upcoming period, according to Wolfe Research is $50 based on the research report published on June 27, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see QGEN reach a price target of $44. The rating they have provided for QGEN stocks is “Equal Weight” according to the report published on December 19th, 2023.
QGEN Trading at -1.99% from the 50-Day Moving Average
After a stumble in the market that brought QGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.51% of loss for the given period.
Volatility was left at 1.50%, however, over the last 30 days, the volatility rate increased by 1.43%, as shares surge +0.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.00% upper at present.
During the last 5 trading sessions, QGEN rose by +0.54%, which changed the moving average for the period of 200-days by +2.85% in comparison to the 20-day moving average, which settled at $45.27. In addition, Qiagen NV saw 2.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QGEN starting from Sackers Roland, who proposed sale 25,000 shares at the price of $46.00 back on Sep 11 ’24. After this action, Sackers Roland now owns shares of Qiagen NV, valued at $1,150,000 using the latest closing price.
Stock Fundamentals for QGEN
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.64 for the gross margin
The net margin for Qiagen NV stands at 0.04. The total capital return value is set at 0.1. Equity return is now at value 2.07, with 1.22 for asset returns.
Based on Qiagen NV (QGEN), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 9.7.
Currently, EBITDA for the company is 650.58 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 5.52. The receivables turnover for the company is 5.14for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
To sum up, Qiagen NV (QGEN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
